"10.1371_journal.pone.0104227","plos one","2014-11-06T00:00:00Z","Ludmilla de Plater; Anne Vincent-Salomon; Frédérique Berger; André Nicolas; Sophie Vacher; Eléonore Gravier; Aurélie Thuleau; Narjesse Karboul; Marion Richardson; Clément Elbaz; Elisabetta Marangoni; Ivan Bièche; Xavier Paoletti; Sergio Roman-Roman; Patricia A Culp; Bernard Asselain; Véronique Diéras; Didier Decaudin","Laboratory of preclinical investigation, Translational Research Department, Institut Curie, Paris, France; Department of Tumor Biology, Institut Curie, Paris, France; Department of Biostatistics, Institut Curie, Paris, France; INSERM U900, Paris, France; Department of Genetics, Institut Curie, Paris, France; Translational Research Department, Institut Curie, Paris, France; AbbVie Biotherapeutics, Redwood City, California, United States of America; Department of Oncogenetic, Institut Curie, Paris, France","Conceived and designed the experiments: DD PAC. Performed the experiments: LDP SV AT NK MR CE. Analyzed the data: LDP AVS AN FB EG IB. Contributed reagents/materials/analysis tools: EM XP SRR BA VD. Contributed to the writing of the manuscript: LDP DD.","Patricia Culp is an employee of AbbVie Biotherapeutics, which is developing PDL192 clinical therapeutic approach. Patents related to this study include Therapeutic use of anti-tweak receptor antibody, WO 2009020933 (A2). There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","11","Ludmilla de Plater","LDP",18,TRUE,2,6,6,NA,TRUE,TRUE,FALSE,0,NA,FALSE
